NEWS & ARTICLES
BHE & OM1 PARTNER TO DELIVER RHEUMATOLOGY REGISTRIES THROUGH IHD
MAY 14, 2019
Research-Grade, Analytic-Ready Rheumatology Data at Your Fingertips through the IHD Platform What would you do with rapid access to analytics and insights from hundreds of thousands of rheumatology patients? Bringing together the largest linked, longitudinal rheumatology condition registries with the industry-leading Instant Health Data (IHD) platform, OM1 and BHE join forces to deliver a powerful[…]
CMS CITES OM1 LED OUTCOMES STANDARDIZATION EFFORT IN TREATMENT RESISTANT DEPRESSION MEMO
FEB 15, 2019
Read the decision memo: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=292
WHITE PAPERS
From Big Data to Measurable Outcomes: OBC
JUL 6, 2017
A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Improving Performance under Bundled Care
NOV 5, 2016
The field of medicine is changing rapidly due to two major disruptions – the application of artificial intelligence, such as machine and deep learning and the shift from fee-for-service to value-based payment models. These innovations, which are occurring simultaneously, are fundamentally altering how data are used and how care is provided. To survive in this[…]
WEBINARS
Aug 30 – Next Generation Registries: Big Data, Advanced Analytics, More Dynamic Evidence
AUG 14, 2018
August 30, 2018 – 2:00 – 3:00 pm ET Registries continue to be a critical part of the real-world evidence equation, but over time they have become too trialized, too burdensome, and too separated from real clinical practice. Emerging methodologies, data digitization, and cognitive technologies have set the path for drastic changes needed to address[…]
Using Big Data Like Biomarkers to Advance Clinical Development & Commercialization
MAR 5, 2018
March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]